IP Library Granted Patent US 10,624,864
Granted Patent B2
US 10,624,864 · App. 16/258,204 · Granted Apr 21, 2020

Epinephrine formulations

Inventors: Suketu Sanghvi (Kendall Park, NJ); Vinayagam Kannan (Morris Plains, NJ); Matthew Kenney (New Haven, MI)
Assignee: PAR PHARMACEUTICAL, INC.
A61K31/137A61K9/0019A61K9/08A61K47/12A61K9/0014A61K9/0048A61K9/0073
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,624,864
App. No.
16/258,204
Granted
Apr 21, 2020
Kind
B2
Abstract

Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.

Claims (25)

1. A pre-filled syringe containing a composition, the composition comprising:

epinephrine and/or salts thereof,

an antioxidant present at a concentration of in the range of about 0.1 to 0.9 mg/mL,

a buffer system, the buffer system comprising tartaric acid,

sodium chloride as a tonicity regulating agent at a concentration of in the range of about 6 to 7.5 mg/mL,

a preservative, and

disodium edetate dihydrate as a transition metal complexing agent at a concentration of in the range of about 0.01 to 0.4 mg/mL,

wherein the buffer system provides a resistance to a pH change such that the composition has a pH of in the range of about 3.5 and 4.0 after 18 months of shelf life, and wherein after 18 months of storage at between 23° C. and 32° C. and between 55% RH and 70% RH, the composition comprises about 3% or less of D-Epinephrine.

2. The pre-filled syringe of claim 1 , wherein the composition has a pH of in the range of about 3.5 and 4.0 after 24 months of shelf life.

3. The pre-filled syringe of claim 1 , wherein the composition has a pH of in the range of about 3.5 and 4.0 after 30 months of shelf life.

4. The pre-filled syringe of claim 1 , wherein the composition has a pH of in the range of about 3.5 and 4.0 after 36 months of shelf life.

5. The pre-filled syringe of claim 1 , wherein the composition has an initial pH of in the range of about 3.5 and 4.5.

6. The pre-filled syringe of claim 1 , wherein the composition has a pH after 18 months of shelf life of no more than about 1 unit different than an initial pH of the composition.

7. The pre-filled syringe of claim 1 , wherein the composition has a pH after 24 months of shelf life of no more than about 1 unit different than an initial pH of the composition.

8. The pre-filled syringe of claim 1 , wherein the composition has a pH after 30 months of shelf life of no more than about 1 unit different than an initial pH of the composition.

9. The pre-filled syringe of claim 1 , wherein the composition has a pH after 36 months of shelf life of no more than about 1 unit different than an initial pH of the composition.

10. The pre-filled syringe of claim 1 , wherein the buffer system has a pKa value in the range of about 2 to 5.

11. The pre-filled syringe of claim 1 , wherein the buffer system has a pKa value in the range of about 3 to 4.5.

12. The pre-filled syringe of claim 1 , wherein the buffer system has a pKa value of about 4.

13. The pre-filled syringe of claim 1 , wherein the buffer system has a pKa value that is within 1 unit of an initial pH of the composition without the buffer system.

14. The pre-filled syringe of claim 1 , wherein the composition has an initial pH of about 4.

15. The pre-filled syringe of claim 1 , wherein after 24 months of storage at between 23° C. and 32° C. and between 55% RH and 70% RH, the composition comprises about 3% or less of D-Epinephrine.

16. The pre-filled syringe of claim 1 , wherein after 30 months of storage at between 23° C. and 32° C. and between 55% RH and 70% RH, the composition comprises about 3% or less of D-Epinephrine.

17. The pre-filled syringe of claim 1 , wherein after 36 months of storage at between 23° C. and 32° C. and between 55% RH and 70% RH, the composition comprises about 3% or less of D-Epinephrine.

18. The pre-filled syringe of claim 1 , wherein the composition with the buffer system has a higher pH after 18 months of shelf life than what it would otherwise have been without the presence of the buffer system.

Assignments (12)
SHORT FORM INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 6, 2025
From: PH HEALTH LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 073508/0830 →
RELEASE OF SECURITY INTEREST IN CERTAIN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (068461/0692) Recorded Aug 4, 2025
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: ENDO OPERATIONS LIMITED
Reel/Frame 072343/0897 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2025
From: ENDO OPERATIONS LIMITED
To: PH HEALTH LIMITED
Reel/Frame 072131/0540 →
SECURITY INTEREST Recorded Jul 22, 2024
From: ENDO BIOLOGICS LIMITED; ENDO OPERATIONS LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 068469/0001 →
SECURITY INTEREST Recorded Jul 19, 2024
From: ENDO BIOLOGICS LIMITED; ENDO OPERATIONS LIMITED
To: GOLDMAN SACHS BANK USA
Reel/Frame 068461/0692 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2024
From: ENDO USA, INC.
To: ENDO OPERATIONS LIMITED
Reel/Frame 067245/0492 →
RELEASE OF SECURITY INTEREST Recorded Apr 26, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH HOLDINGS, LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.); ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0682 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR PHARMACEUTICAL COMPANIES, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0491 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2024
From: PAR PHARMACEUTICAL, INC.
To: ENDO USA, INC.
Reel/Frame 067203/0686 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 17, 2021
From: ASTORA WOMEN'S HEALTH LLC; ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS INC.; PAR PHARMACEUTICAL, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 057538/0978 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded May 26, 2020
From: ASTORA WOMEN'S HEALTH LLC; ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS INC.; PAR PHARMACEUTICAL, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 052752/0269 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2019
From: SANGHVI, SUKETU; KANNAN, VINAYAGAM; KENNEY, MATTHEW
To: PAR PHARMACEUTICAL, INC.
Reel/Frame 048193/0286 →